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Background: Smooth muscle cell (SMC) migration and proliferation are important in the development of intimal
hyperplasia, the major cause of vein graft failure. Proteases of the plasminogen activator (PA) system and of the matrix
metalloproteinase (MMP) system are pivotal in extracellular matrix degradation and, by that, SMC migration. Previ-
ously, we demonstrated that inhibition of both protease systems simultaneously with viral gene delivery of the hybrid
protein TIMP-1.ATF, consisting of the tissue inhibitor of metalloproteinase-1 (TIMP-1) and the receptor-binding
amino terminal fragment (ATF) of urokinase, reduces SMC migration and neointima formation in an in vitro restenosis
model using human saphenous vein cultures more efficiently than both protease systems separately. Because use of viral
gene delivery is difficult in clinical application, this study used nonviral delivery of TIMP-1.ATF plasmid to reduce vein
graft disease in a murine bypass model. Nonviral gene transfer by electroporation was used to avert major disadvantages
of viral gene delivery, such as immune responses and short-term expression.
Methods: Plasmids encoding ATF, TIMP-1, TIMP-1.ATF, or luciferase, as a control, were injected and electroporated
in both calf muscles of hypercholesterolemic apolipoprotein E3-Leiden (APOE*3Leiden) mice (n  8). One day
after electroporation, a venous interposition of a donor mouse was placed into the carotid artery of a recipient
mouse. In this model, vein graft thickening develops with features of accelerated atherosclerosis. Vein grafts were
harvested 4 weeks after electroporation and surgery, and histologic analysis of the vessel wall was performed.
Results: Electroporation-mediated overexpression of the plasmid vectors resulted in a prolonged expression of the
transgenes and resulted in a significant reduction of vein graft thickening (ATF: 36%  9%, TIMP-1: 49%  5%,
TIMP-1.ATF: 58%  5%; P < .025). Although all constructs reduced vein graft thickening compared with the controls,
the luminal area was best preserved in the TIMP-1.ATF-treated mice.
Conclusion: Intramuscular electroporation of TIMP-1.ATF inhibits vein graft thickening in vein grafts in carotid arteries
of hypercholesterolemic mice. Binding of TIMP-1.ATF hybrid protein to the u-PA receptor at the cell surface enhances
the inhibitory effect of TIMP-1 on vein graft remodeling in vitro as well as in vivo and may be an effective strategy to
prevent vein graft disease. ( J Vasc Surg 2010;51:429-37.)
Clinical Relevance.Venous bypass graft failure is a serious clinical problem that occurs in up to 40% to 60% of patients
after bypass surgery, and reinterventions are often required both in cardiac and peripheral vascular disease. Smooth
muscle cell migration and proliferation in the vessel wall, mediated by proteases of the plasminogen activator system
and matrix metalloproteinase system, are important in the development of vein graft disease. Nonviral gene transfer
by intramuscular electroporation of the hybrid protein TIMP-1.ATF, consisting of the tissue inhibitor of
metalloproteinase-1 (TIMP-1) and the receptor-binding amino terminal fragment (ATF) of urokinase, to inhibit
these proteases directly at the cell surface, suppresses the development of vein graft thickening, without the major
disadvantages of viral gene delivery such as immune responses and short-term expression, and therefore may be a
potential therapeutic tool to improve vein graft disease.
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important factors in the development of vein graft thicken-
ing after vein graft surgery, eventually resulting in occlusion
of the vessel lumen.1,2 This vein graft failure may lead to
tissue ischemia, and frequently, reinterventions or limb
amputations are inevitable if the grafts fail.3
Smooth muscle cell (SMC) migration and proliferation
as well as deposition and turnover of extracellular matrix
(ECM) proteins occurring early after reconstruction largely
contribute to the complex process of intimal hyperplasia.4,5
Together with the influx of lipid-loaded macrophages,
accelerated atherosclerosis of the vein graft develops.6,7
Members of the matrix metalloproteinases (MMP) family
and the plasminogen activator (PA) system are important in
SMC migration and the associated degrading and turnover
of ECM proteins.8
MMPs are a family of 25 zinc-dependent proteases,
of which most have been detected in vascular cells.9 They
are not only able to degradate (vascular) ECM proteins
such as collagen and elastin but may also be involved in
activation of growth factors and proenzymes.10,11 Further-
more, MMPs are up-regulated in vein grafts after vascular
injury.12 Tissue inhibitors of metalloproteinases (TIMP),
together with inflammatory cells and cytokines, regulate
the expression of MMPs in the vein grafts and arteries, and
overexpression of TIMPs can prevent SMCmigration.13-15
Adenoviral-mediated overexpression of several TIMPs in-
hibited vein graft thickening in vitro as well as in vivo.16-18
Urokinase-type plasminogen activator (u-PA) and
tissue-type plasminogen activator (t-PA), both members of
the serine protease family, are also upregulated in diseased
blood vessels.8 Because u-PA is recruited to the cell surface
by its receptor u-PAR, it plays a central role to pericellular
proteolysis. This results in cell surface-bound activation of
plasmin, which can degrade ECM both directly and indi-
rectly through activation of MMP proenzymes.19
Previously, we demonstrated that inhibitory effects of
TIMP-1 could be enhanced by the binding of TIMP-1 to
the aminoterminal fragment of urokinase (ATF), which
contains the receptor-binding domain of u-PA. By binding
TIMP-1 to u-PAR, this protein was not only anchored
directly to the cell surface but also prevented local activa-
tion of plasminogen by blocking the binding of u-PA to its
receptor (Fig 1). In cultured human saphenous vein seg-
ments, adenoviral administration of the hybrid protein
TIMP-1.ATF inhibited matrix degeneration and SMC mi-
gration, which resulted in a reduction of neointima forma-
tion in vitro.20
In the present study, the effect of TIMP-1.ATF on vein
graft thickening and remodeling in vitro was studied in hyper-
cholesterolemic apolipoprotein E3-Leiden (APOE*3Leiden)
mice, using a murine model for vein graft disease.21 Within 4
weeks after placing a venous interposition in the carotid artery
of these mice, vein graft thickening with signs of accelerated
atherosclerosis uniformly develops.22
For the successful application of TIMP-1.ATF in vivo,
long-term and sufficient circulating levels of TIMP-1.ATF
protein are essential. Gene therapy is an attractive strategyto achieve this: no repeated administration of therapeutic
proteins is necessary because the therapeutic protein will be
produced in vivo. Moreover, other therapies, such as phar-
macologic interventions to prevent vein graft disease, are
still disappointing.23
Although adenoviral gene transfer is commonly used
for in vivo gene transfer in mice, several negative side effects
discourage the use of these adenoviral vectors. Systemic
delivery of adenoviruses such as through venous injection
results in transduction of predominantly the liver and may
lead to strong systemic inflammatory and immunologic
responses. Local transduction of the musculature may be
less harmful, but the transduction efficiency in musculature
is generally low after adenoviral delivery and is accompa-
nied with only short-term expression. As an alternative,
nonviral intramuscular electroporation-mediated gene
transfer of a TIMP-1.ATF expression plasmid was used to
obtain circulating levels of TIMP-1.ATF protein.24,25
In this study, we demonstrate that this method results
in long-term functional serum levels of TIMP-1.ATF. Fur-
thermore, cell surface-bound inhibition of u-PA and the
MMP system with the hybrid protein TIMP-1.ATF re-
duces vein graft thickening and vascular remodeling in
hypercholesterolemic APOE*3-Leiden mice.
MATERIALS AND METHODS
Plasmid construction. To construct all plasmid vec-
tors, mutated ATF, TIMP-1, and TIMP-1.mATF compli-
mentary DNA, previously constructed in our lab,20 were
cloned into a pcDNA3.1() expression cassette (Invitro-
gen, The Netherlands). In the human aminoterminal frag-
Fig 1. Schematic representation shows the mechanism of tissue
inhibitor of metalloproteinase-1 linked to the amino terminal
fragment (TIMP-1.ATF) activity. Pericellular inhibition of plasmin
and matrix metalloproteinase (MMP) activity is accomplished by
anchoring TIMP-1 via ATF to the urokinase-type plasminogen
activator (u-PA) receptor (u-PAR). This process is enhanced by
competing of TIMP-1.ATF with native u-PA for binding to u-
PAR, resulting in reduction of conversion of plasminogen to
plasmin and subsequently, pro-MMP activation.ment of u-PA (hATF), site-specific mutations were intro-
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u-PA (mATF), thus enabling binding to the murine u-
PAR.26 Photinus pyralis (firefly) luciferase reporter gene,
obtained from the pGL3 control vector (Promega, The
Netherlands), was cloned into the same pcDNA3.1 cas-
sette. All plasmid DNA was prepared using DH5 Esche-
richia coli (Invitrogen) and QIAfilter Plasmid Giga Kits
(Qiagen, The Netherlands). Plasmid DNA was dissolved in
Endofree tris(hydroxymethyl)aminomethane-ethylenediami-
netetraacetic acid (TE) buffer (Qiagen) at a final concen-
tration of 3.5 mg/mL.
Mice. Animal experiments were approved by the Ani-
mal Welfare Committee of The Netherlands Organization
for Applied Scientific Research (TNO, The Netherlands).
For all experiments, 14-week-old male heterozygous
APOE*3Leiden animals on a C57BL/6 background,
crossbred for at least 20 generations in our laboratory, were
used. APOE*3Leiden mice develop a diet-dependent hy-
percholesterolemia and spontaneous atherosclerosis.27,28
Animals were fed with a cholesterol-enriched high-fat diet,
containing 1% cholesterol and 0.05% cholate (Arie Blok
BV, Woerden, The Netherlands), starting 4 weeks before
surgery and continued during the entire experiment.22 All
mice received water and food ad libitum.
One week before surgery and at sacrifice, a cholesterol
esterase, cholesterol oxidase reaction was used to determine
cholesterol levels in serum (Chol R1, Roche Diagnostics,
Woerden, The Netherlands). Mice with an overall mean
weight of 27.1 0.3 g were allocated randomly to the four
experimental groups (n  8 per group).
Intramuscular electroporation. Before electropora-
tion, surgery, and sacrifice, mice were anesthetized by an
intraperitoneal injection with a combination of midazolam
(5 mg/kg, Roche), Medetomidine, (0.5 mg/kg; Orion,
Espoo, Finland), and fentanyl (0.05mg/kg; Janssen-Cilag,
The Netherlands).
To obtain circulating levels of mATF, TIMP-1, and
TIMP-1.mATF protein, pcDNA3.1 vectors encoding for
these proteins were injected in the calf muscle, followed by
electroporation using an optimized electroporation proto-
col as previously published.24,29,30 Briefly, plasmid DNA
(in total 50 g/leg), dissolved in 30 L TE buffer and
140mM saline, was injected in each of the calf muscles,
followed by eight 10-millisecond electrical pulses at 200
V/cmwith a frequency of 1 Hz. The pulses were generated
with a Square Wave Electroporator ECM 830 and admin-
istered using Caliper Electrodes (BTX; Harvard Apparatus,
Holliston, Mass). As a control, pcDNA3.1-luciferase was
used. Electroporation was performed 1 day before vein
graft surgery.
Murine vein graft model. One day after electropora-
tion, a venous interposition graft was placed in the carotid
artery as described by Zou et al.21 In brief, caval veins of
donor mice serving as vein grafts were harvested and pre-
served in 0.9% saline containing 100 IU heparin. In the
recipient mice, the right carotid artery was dissected free
from its surroundings and cut midway. Next, a polyethyl-
ene cuff was placed at the end on both sides. The artery waseverted around the cuff and fixated by a suture ligation at
both ends. Finally, the caval vein was grafted by sleeving the
ends of the vein over two everted ends of the carotid artery
and fixated with a ligation as well. Please see Fig S1, (online
only) for photographs of this vein graft model.
Vein graft thickening quantification and immuno-
histochemistry. Mice were sacrificed 28 days after surgery
for histologic analysis (n  8 per group). Tissue segments
were harvested after in vitro perfusion fixation with 4%
formaldehyde, fixated overnight, and paraffin-embedded.
To quantify vein graft thickening, sequential cross-sections
were made throughout the embedded vein grafts. For each
mouse, six representative sections per vessel segment were
used after being stained for hematoxylin-phloxine-saffron
(HPS).
Image analysis software was used to quantify the vein
graft thickening (Qwin; Leica, Wetzlar, Germany). Vein
graft thickening was defined as the area between the lumen
and adventitia and determined by subtracting the luminal
area from the total vessel wall area, because no obvious
boundary between intima and media can be detected in
these venous segments due to the lack of internal elastic
lamina.31 The mean per mouse was used to determine the
mean per group. All measurements and calculations were
done in a single blinded fashion.
The composition of vein graft thickening was visualized
by HPS staining and immunohistochemistry. MMP-2,
MMP-9, and membrane-type (MT)-MMP-1 were visual-
ized at several time points with antibodies against MMP-2
(mouse anti-human), MMP-9 (goat anti-human) and MT-
MMP-1 (rabbit anti-mouse; all with a dilution of 1:100 and
purchased from Santa Cruz Biotechnology Inc, Santa
Cruz, Calif). Local presence of u-PA and u-PAR in the
vessel wall was demonstrated with polyclonal human u-PA
antibodies (1:150; Abgent, San Diego, Calif) and u-PAR
(goat anti-mouse, 1:50; R&D Systems, Minneapolis,
Minn). SMCs were detected with -SMC actin staining
(anti-SM -actin, 1:750, Roche Applied Biosciences).
Smooth muscle cells immunopositive areas in the vein graft
thickening were calculated as a percentage of the total vein
graft area in cross-sections by means of image analysis
software (Qwin, Leica). CD45-positive leucocytes were
determined with a CD45 rat anti-mouse antibody (1:200,
BD Biosciences Pharmingen, San Diego, Calif). The num-
ber of positively stained cells per microscopic view (original
magnification150) was scored in a single blinded fashion.
Enzyme-linked immunoabsorbent assay of TIMP-1.
mATF. Serum samples were collected to determine the
circulating levels of TIMP-1.mATF at 7, and 28 days after
electroporation. TIMP-1.mATF concentrations were mea-
sured using an u-PA enzyme-linked immunosorbent assay
(ELISA) with a validated standard curve of human u-PA
and monoclonals produced in our laboratory as described
previously.32 The concentrations are expressed as human
urokinase equivalents.
Statistical analysis. The group size of eight animals
was used for all experiments, and was chosen based on a
standard power calculation, using a power of 90%, an  of
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ence between groups of at least 20%. Data are presented as
mean  standard error of the mean (SEM). Statistical
significance was calculated in SPSS 15.0. software (SPSS
Inc, Chicago, Ill). Overall comparisons between groups
were performed with the one-way analysis of variance, and
thereafter, differences between groups were determined
using the t test. Ordinal scores (CD45 immunohistochem-
istry) were compared using the Pearson 2 test. Values of
P 	 .05 were considered statistically significant.
RESULTS
Expression of MMPs and proteases of the PA sys-
tem in murine vein grafts. The expression of various
members of the MMP family was confirmed by the pres-
ence of MMP-2, MMP-9, and MT-MMP-1 protein re-
vealed by immunohistochemical staining on cross-sections
of vein grafts, harvested at several time points (before
surgery and at T 1, 7, and 28 days after surgery; Fig 2,A).
MMP-2 could not be detected in untreated caval veins;
however, MMP-2 was present in infiltrating cells at T  1
and in infiltrating cells, such as in the thickened vein graft,
at a later time point. At 4 weeks after surgery, MMP-2
was abundantly present throughout the vein graft thicken-
ing and was localized to SMC-rich regions as assessed with
immunohistochemistry on serial sections (anti-SM -actin
positive) and evaluated byMMP-2 expression in relation to
cell morphology.
MMP-9 and MT-MMP-1 could be detected in un-
treated caval veins and was also present in the infiltrating
cells at the early time points. Expression of MMP-9 and
MT-MMP-1 increased in time. MMP-9 was also present in
regions that contain activated endothelial cells and adher-
ing leucocytes. So, during the remodeling processes of vein
grafts, an abundant expression of the various MMPs could
be detected throughout the vessel wall.
Immunohistochemical staining performed on cross-
sections of the vein grafts for u-PA and its receptor u-PAR
demonstrated the expression of proteases of the plasmino-
gen activator system. Both u-PA and u-PAR were seen
throughout the whole vessel wall (Fig 2).
These data show the presence of the major members of
the MMP family and the PA system in the vein grafts and
underscore the rationale for the therapeutic strategy to
inhibit the activity of these proteases at the cell surface in
the vein graft vessel wall, using the u-PAR as a docking site
for the hybrid TIMP.ATF protein.
Expression of TIMP-1.mATF after intramuscular
electroporation-mediated gene transfer. The circulating
protein levels of TIMP-1.mATF are depicted in Fig 3.
Blood samples were collected before electroporation and at
8 and 28 days after intramuscular injection and electropo-
ration with the plasmid pTIMP-1.mATF. Serum levels of
TIMP-1.mATF, as determined by ELISA, were 5.8  0.9
ng/mL and 6.3  2.3 ng/mL u-PA equivalents, respec-
tively (difference not significant), indicating that the ex-
pression of TIMP-1.mATF was sustained during the entire
experimental period. No TIMP-1.mATF could be detectedin the control groups or in the samples obtained before
electroporation.
Effects of TIMP-1.mATF on vein graft thickening
in vitro. To study the effect of TIMP-1.mATF on vein
graft thickening in vitro, hind limbs of hypercholester-
olemicmice were injected and electroporated with plasmids
encoding for mATF, TIMP-1, or TIMP-1.mATF, or lucif-
erase as a control. One day after electroporation, a venous
interposition was placed in the carotid artery of hypercho-
lesterolemic APOE*3Leiden mice (n  8 per group). All
mice were fed with a mild Western-type diet for 1 month
before surgery and electroporation.
Mean serum cholesterol level in all mice was 12.9 0.8
mmol/L. There were no significant differences between
groups and cholesterol levels, and body weights of all mice
did not change significantly during the experiment (data
not shown).
Mice were sacrificed 4 weeks after vein graft placement,
vessel segments were harvested, and vein graft remodeling
was analyzed by quantitative morphometry. Typical repre-
sentative cross-sections are shown in Fig 4, C.
Vein graft thickening was significantly inhibited in all
groups compared with the control (Fig 4, A). Electropora-
tion with the plasmids pATF and pTIMP-1 resulted in a
reduction of 36%  9% and 49%  5%, respectively com-
pared with the control (control: 0.62  0.09 mm2, ATF:
0.40  0.05 mm2, and TIMP-1: 0.32  0.03 mm2; P 
.025 and P 	 .002). Treatment with pTIMP-1.mATF
lowered vein graft thickening by 58%  5% (TIMP-
1.mATF: 0.26  0.03 mm2; P 	 .001). A significantly
stronger inhibition of vein graft thickening, 4 weeks after
surgery, was observed after electroporation with pTIMP-
1.mATF compared with treatment with pATF (P  .022).
The ratio of lumen/total cross-sectional area of the
vessel was also significantly increased in the treated
groups compared with the control. This indicates a
beneficial effect of both TIMP-1 and ATF on (patho-
logic) vascular remodeling (Fig 4, B). Moreover, the
effect was even stronger after electroporation with
pTIMP-1.mATF (P 	 .05).
The effect on plaque composition of the vein graft
thickening after electroporation was studied by immuno-
histochemical analysis for the presence of SMCs andCD45-
positive leucocytes. Relative SM -actin-positive areas were
not significantly altered between groups 4 weeks after
surgery (control: 19.9%  4.3%, mATF: 15.0%  4.2%,
TIMP-1: 18.6%  2.5%, TIMP-1.mATF: 20.1%  3.8%).
Also, no significant differences in influx of inflammatory
cells, monitored as CD45-positive cells, were observed
(data not shown).
DISCUSSION
In this study, we clearly demonstrate that in vitro
thickening of the vein graft can be significantly inhibited
after nonviral delivery of mATF, TIMP-1, and the hybrid
protein TIMP-1.mATF. Moreover, TIMP-1.mATF had
the most beneficial profile regarding vascular remodeling of
the vein graft with preservation of luminal area.
ry, u-
JOURNAL OF VASCULAR SURGERY
Volume 51, Number 2 Eefting et al 433Previous reports have documented increased MMPs
and PA activity in (human) vein grafts, and the expression
of the TIMPs, the natural regulators of MMPs, during
Fig 2. Representative cross-sections of untreated murine
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grafts, harvested 4 weeks after surgery show expression of
em proteases.MMP-2,MMP-9, membrane-type-MMP-1
nd u-PA receptor (u-PAR) were visualized with specific
,The expression ofMMP-2,MMP-9, andMT-MMP-1 is
graft (untreated vein graft and 1, 7, 14, and 28 days after
and also in the thickened vein graft at later time points and
ainly colocalizing with smooth muscle cells. Expression of
also be detected in activated endothelial cells and adhering
PA and u-PAR are expressed throughout the whole vesselvein
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-9 cantion and proliferation, particularly prominent in the first 6
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thickening and compromises long-term graft patency.19,34
Suppressing these activities in the first months by overex-
pression of their regulators is a promising approach to
prevent vascular diseases.
In a previous study, we showed that intimal hyperplasia
was inhibited substantially when the MMP and PA systems
were restrained simultaneously by adenoviral gene transfer
in cultured segments of the human saphenous vein.20 In
the current study, we extended this observation to an in
vivo situation using a murine model for vein graft disease
combined with electroporation-mediated gene transfer of
expression plasmids encoding for the hybrid protein TIMP-
1.mATF.
Various reports describe the effects on vein graft disease
of overexpression of TIMP-1, -2, and -3. George et al16,17
showed that adenoviral gene transfer of the TIMP-1 and -2
gene inhibits SMC migration and neointima formation in
human saphenous veins in vitro. Later, they inhibited
MMP activity in vein grafts in vitro with overexpression of
TIMP-3. TIMP-2, used as a control in this study, had no
effect on vein graft thickening in their bypass model, both
in vitro and in vivo.18 This is in contrast with Hu et al,35
who studied the effect of local adenoviral-mediated gene
transfer of TIMP-2 on vein graft remodeling. They de-
scribe a reduction in vein graft diameter and vein graft
thickening.35 Finally, Puhakka et al36,37 showed the effect
of adenoviral delivery of TIMP-1 as well in an arterial
Fig 3. Plasma levels of TIMP-1.mATF (urokinase type) after
intramuscular electroporation (in ng/mL) are shown before elec-
troporation, and at 8 and 28 after intramuscular injection and
electroporation of pTIMP-1.mATF (n 8 per group) as detected
with a urokinase-type plasminogen activator enzyme-linked immu-
nosorbent assay. No TIMP-1.mATF levels could be measured in
the control groups and before electroporation. Difference between
both time points is not significant. The error bars signify the
standard error of the mean. mATF, Murinized amino terminal
fragment; TIMP-1, tissue inhibitor of metalloproteinase-1;
pTIMP-1, plasmid vector encoding TIMP1.model for restenosis as in a vein graft model. Although bothmodels showed an inhibitory effect of TIMP-1 on resteno-
sis, the effect in the vein graft model only lasted for 2 weeks,
and plaque size was similar again to the control group 4
weeks after surgery.36,37 These studies underscore the po-
tency of gene therapy and the therapeutic potential of
inhibiting MMP activity in preventing vein graft disease.
In all described studies, adenoviral-mediated gene ther-
apy was used to deliver the TIMPs to the target tissue. If
clinical application is considered, gene therapy has inher-
ited difficulties. Therefore, we used intramuscular electro-
poration, an alternative gene deliverymethod in the present
study. With this technique, drawbacks of viral gene deliv-
ery, such as low transduction efficiency for vascular tissue
and the preexisting immunity, can be prevented and long-
term transgene expression can be achieved.25
Although newer generations of adenoviral vectors are
less immunogenic and are more efficient in vascular infec-
tion, these adenoviruses are still not fully usable for the
human situation.38,39 Particularly referring to a clinical
setting, this is of importance because it is thought that
explantable saphenous veins are more suitable for extracor-
poreal adenoviral than for intravenous or intramuscular
gene therapy. The fact that adenoviral gene transfer, with
the complications of short-term expression and induction
of an inflammatory reaction, should be considered as less
suitable for vein graft gene transfer opens up new perspec-
tives for electroporation-mediated plasmid-based gene
transfer with its relatively beneficial safety profile and long-
lasting expression of the introduced genes.
In our study, prolonged circulating levels of the transgenes,
including the hybrid protease inhibitor TIMP1.mATF, were
obtained after intramuscular electroporation-mediated gene
transfer into the calf muscle of the mouse. This resulted in
an effect on vascular remodeling in distant vein grafts (ie,
inhibition of vein graft thickening in grafts interpositioned
in the carotid arteries). The inhibitory effect of pTIMP-
1.mATF was, with a 58% reduction, the most powerful,
whereas the effect of pTIMP-1 was less strong (49%). Also,
electrodelivery of pATF reduced vein graft thickening
(36%), which is in line with our previous findings.40
Next to the observed differences in vein graft thicken-
ing between ATF, TIMP-1 and TIMP-1.mATF, the ratio
between luminal area and the total cross-sectional area was
significantly increased after treatment with pTIMP-
1.mATF compared with the other groups. This indicates a
positive effect on vascular remodeling, because the luminal
area is relatively large compared with the area of total vessel
in the pTIMP-1.mATF-treated mice, suggesting a better
patency in the long run. It is likely that vascular remodeling
is inhibited by TIMP-1.mATF because by binding to the
u-PAR, activation of plasminogen is also blocked together
with the local activation of MMPs.8,20
At sacrifice, no significant reduction in relative SMC
content was found after TIMP-1.mATF treatment or the
individual components. Referring to plaque stability, this is
a favorable situation.41
Synthetic inhibition of MMPs with broad-spectrum
pharmacologic compounds is an alternative method to
ith co
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nonspecific and failed to reduce long-lasting neointima
formation.9,42
Because MMPs not only facilitate SMC migration and
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graft surgery was performed 1 day after intramuscular
ing six sequential sections per segment and are expressed
ith all plasmids resulted in a significant reduction of vein
en the luminal area and total cross-sectional area of the
ted delivery of all plasmids compared with the control.
ps was significant. C, In HPS staining of vein grafts,
omplete circular surface was used to calculate vein graft
ls were stained with antismooth muscle -actin (original
ntrol or indicated by the black line.hloxi
Vein
iden
l frag
Vein
by us
ent w
etwe
edia
grou
the c
nimarelated recruitment of monocytes.10,44,45 In the present
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February 2010436 Eefting et alstudy, however, no effect of TIMP-1.mATF on influx of
inflammatory cells as monitored by CD45 staining could be
observed.
CONCLUSIONS
These data demonstrate that intramuscular electroporation-
mediated gene transfer of TIMP-1.mATF encoding plas-
mid vectors in the calf muscle results in circulating serum
levels of the hybrid protease inhibitor TIMP-1.mATF.
These levels are sufficient to inhibit vein graft thickening
within the first month in vein grafts in carotid arteries of
hypercholesterolemic apolipoprotein E (APOE)*3Leiden
mice. Because TIMP-1.ATF binds selectively to the u-PA
receptor and blocks both MMP and plasmin activity on the
cell-surface, this approach may contribute in preventing
post-interventional restenosis and vein graft disease in by-
passed patients.
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